Legend Biotech (LEGN) Presents Two-Year Analysis of CARTITUDE-1 Showing Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Mye
Go back to Legend Biotech (LEGN) Presents Two-Year Analysis of CARTITUDE-1 Showing Early, Durable and Deepening Responses of Ciltacabtagene Autoleucel (cilta-cel) in Heavily Pretreated Patients with Multiple Mye| (NASDAQ: LEGN) | Delayed: 29.02 +1.09 (3.90%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.93 | 52 Week High | $ | |||
| Open | $28.38 | 52 Week Low | $ | |||
| Day High | $29.46 | P/E | N/A | |||
| Day Low | $28.10 | EPS | $ | |||
| Volume | 1,444,235 | |||||
